Regal Investment Advisors LLC Sells 965 Shares of Merck & Co., Inc. (NYSE:MRK)
Regal Investment Advisors LLC Sells 965 Shares of Merck & Co., Inc. (NYSE:MRK)
Regal Investment Advisors LLC cut its holdings in shares of Merck & Co., Inc. (NYSE:MRK – Get Rating) by 7.1% during the 1st quarter, Holdings Channel reports. The firm owned 12,559 shares of the company's stock after selling 965 shares during the period. Regal Investment Advisors LLC's holdings in Merck & Co., Inc. were worth $1,030,000 as of its most recent filing with the Securities and Exchange Commission.
據Holdings Channel報道，富豪投資顧問公司在第一季度減持了默克公司(Merck&Co.，Inc.)股票7.1%。該公司在此期間出售了965股後，持有該公司12,559股股票。截至最近提交給美國證券交易委員會的文件，富豪投資顧問公司持有的默克公司股份價值1030,000美元。
Other hedge funds have also added to or reduced their stakes in the company. Bromfield Sneider Wealth Advisors bought a new position in Merck & Co., Inc. in the first quarter valued at approximately $79,000. Hikari Power Ltd grew its stake in shares of Merck & Co., Inc. by 5.0% during the first quarter. Hikari Power Ltd now owns 23,630 shares of the company's stock worth $1,939,000 after buying an additional 1,130 shares during the last quarter. ACG Wealth grew its stake in shares of Merck & Co., Inc. by 5.6% during the first quarter. ACG Wealth now owns 13,523 shares of the company's stock worth $1,110,000 after buying an additional 722 shares during the last quarter. Mascoma Wealth Management LLC grew its stake in shares of Merck & Co., Inc. by 36.4% during the first quarter. Mascoma Wealth Management LLC now owns 926 shares of the company's stock worth $76,000 after buying an additional 247 shares during the last quarter. Finally, WealthBridge Investment Counsel Inc. lifted its holdings in shares of Merck & Co., Inc. by 4.1% during the first quarter. WealthBridge Investment Counsel Inc. now owns 87,820 shares of the company's stock worth $7,206,000 after purchasing an additional 3,475 shares during the period. 72.88% of the stock is owned by institutional investors.
其他對衝基金也增持或減持了該公司的股份。Bromfield Sneider Wealth Advisors在第一季度購買了默克公司的一個新頭寸，價值約7.9萬美元。Hikari Power Ltd在第一季度增持了默克公司的股票5.0%。Hikari Power Ltd現在擁有23,630股該公司股票，價值1,939,000美元，此前該公司在上個季度又購買了1,130股。今年第一季度，ACG Wealth在默克公司(Merck&Co.，Inc.)的持股增加了5.6%。ACG Wealth現在擁有13,523股該公司股票，價值1，11萬美元，在上個季度又購買了722股。Masoma Wealth Management LLC在第一季度增持了默克公司(Merck&Co.，Inc.)股票36.4%。Mascoma Wealth Management LLC現在持有該公司926股股票，價值7.6萬美元，上個季度又購買了247股。最後，WealthBridge Investment Counsel Inc.在第一季度增持了4.1%的默克公司股票。WealthBridge Investment Counsel Inc.在此期間又購買了3,475股，目前持有87,820股該公司股票，價值7,206,000美元。72.88%的股份由機構投資者持有。
Merck & Co., Inc. Price Performance
默克公司性價比
Shares of NYSE:MRK opened at $87.41 on Friday. The company's fifty day moving average price is $90.27 and its 200-day moving average price is $85.38. The firm has a market capitalization of $221.04 billion, a price-to-earnings ratio of 13.39, a PEG ratio of 1.17 and a beta of 0.32. Merck & Co., Inc. has a one year low of $70.89 and a one year high of $95.72. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.40 and a quick ratio of 1.14.
紐約證券交易所股票：Mr K上週五開盤報87.41美元。該公司的50日移動均線價格為90.27美元，200日移動均線價格為85.38美元。該公司市值為2,210.4億美元，市盈率為13.39倍，聚乙二醇率為1.17倍，貝塔係數為0.32。默克公司的一年低點為70.89美元，一年高位為95.72美元。該公司的債務權益比為0.75，流動比率為1.40，速動比率為1.14。
Merck & Co., Inc. Announces Dividend
默克公司宣佈分紅
The firm also recently announced a quarterly dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 15th will be issued a dividend of $0.69 per share. This represents a $2.76 annualized dividend and a dividend yield of 3.16%. The ex-dividend date of this dividend is Wednesday, September 14th. Merck & Co., Inc.'s dividend payout ratio is currently 42.27%.
該公司最近還宣佈了季度股息，將於10月7日(星期五)支付。9月15日(星期四)登記在冊的投資者將獲得每股0.69美元的股息。這意味着年化股息為2.76美元，股息收益率為3.16%。本次股息除息日為9月14日星期三。默克公司目前的股息支付率為42.27%。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
A number of brokerages have recently commented on MRK. Atlantic Securities lifted their price target on shares of Merck & Co., Inc. from $105.00 to $110.00 and gave the stock an "overweight" rating in a report on Wednesday, July 13th. Morgan Stanley lifted their price target on shares of Merck & Co., Inc. from $88.00 to $92.00 and gave the stock an "equal weight" rating in a report on Friday, July 29th. SVB Leerink reiterated an "outperform" rating and set a $102.00 price target on shares of Merck & Co., Inc. in a report on Monday, June 6th. Cowen boosted their target price on shares of Merck & Co., Inc. from $95.00 to $102.00 and gave the company a "market perform" rating in a report on Monday, June 27th. Finally, Barclays boosted their target price on shares of Merck & Co., Inc. from $94.00 to $97.00 and gave the company an "overweight" rating in a report on Tuesday, April 12th. Eight investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $97.44.
近期多家券商紛紛對MRK發表評論。大西洋證券將默克公司的股票目標價從105.00美元上調至110.00美元，並在7月13日週三的一份報告中給予該股“增持”評級。摩根士丹利在7月29日星期五的一份報告中將默克公司的股票目標價從88.00美元上調至92.00美元，並給予該股“同等權重”的評級。SVB Leerink在6月6日週一的一份報告中重申了對默克公司的評級，併為默克公司的股票設定了102.00美元的目標價。考恩在6月27日週一的一份報告中將默克公司股票的目標價從95美元上調至102.00美元，並給予該公司“市場表現”評級。最後，巴克萊在4月12日週二的一份報告中將默克公司股票的目標價從94.00美元上調至97.00美元，並給予該公司“增持”評級。8名投資分析師對該股的評級為持有，9名分析師給出了買入評級，兩名分析師對該股發出了強烈的買入評級。根據MarketBeat的數據，該公司目前的共識評級為“適度買入”，共識目標價為97.44美元。
Merck & Co., Inc. Company Profile
默克公司公司簡介
(Get Rating)
(獲取評級)
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.
默克公司是一家全球性的醫療保健公司。它通過兩個部門運作，製藥和動物健康。製藥部門提供腫瘤學、醫院急性護理、免疫學、神經科學、病毒學、心血管和糖尿病等領域的人類健康藥物產品，以及疫苗產品，如預防性兒科、青少年和成人疫苗。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Merck & Co., Inc. (MRK)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- 免費獲取StockNews.com關於默克公司的研究報告(MRK)
- MarketBeat：回顧中的一週8/1-8/5
- 如何利用高貝塔係數股票最大化你的投資利潤
- 克羅諾斯集團(Cronos Group Inc.)營收上升，是時候收購了嗎？
- 蘋果為何可能在年底創下歷史新高
- Beyond Meat不是沒有希望，而且它很便宜
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Get Rating).
想看看還有哪些對衝基金持有MRK嗎？訪問HoldingsChannel.com獲取默克公司(NYSE：MRK-GET Rating)的最新13F文件和內幕交易信息。
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
每天收到默克公司的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對默克公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。